Epigenetic diagnostics of cancer - the application of DNA methylation markers

• Autorzy: Paluszczak J , Baer-Dubowska W
• Języki publikacji: EN

Abstrakty

EN

In recent years it has become apparent that epigenetic events are potentially equally responsible for cancer initiation and progression as genetic abnormalities. DNA methylation is the main epigenetic modification in humans. Two DNA methylation lesions coexist in human neoplasms: hypermethylation of promoter regions of specific genes within a context of genomic hypomethylation. Aberrant methylation is found at early stages of carcinogenesis and distinct types of cancer exhibit specific patterns of methylation changes. Tumor specific DNA is readily obtainable from different clinical samples and methylation status analysis often permits sensitive disease detection. Methylation markers may also serve for prognostic and predictive purposes as they often reflect the metastatic potential and sensitivity to therapy. As current findings show a great potential of recently characterised methylation markers, more studies in the field are needed in the future. Large clinical studies of newly developed markers are especially needed. The review describes the diagnostic potential of DNA methylation markers.

Słowa kluczowe

EN

DNA hypermethylation; DNA hypomethylation; epigenetics; application; DNA methylation marker; methylation marker; cancer; diagnostics

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 2006
• Tom: 47
• Numer: 4
• Opis fizyczny: p.365-375,ref.

Twórcy

autor

Paluszczak J

• Department of Pharmaceutical Biochemistry, University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland

autor

Baer-Dubowska W

• Department of Pharmaceutical Biochemistry, University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland

Bibliografia

• Ahuja N, Li Q, Mohan AL, Baylin SB, Issa J-P, 1998. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 58: 5489-5494.
• Alaminos M, Davalos V, Cheung N-KV, Gerald WL, Esteller M, 2004. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 96: 1208-1219.
• Anacleto C, Rossi B, Lopes A, Soares FA, Rocha JC, Caballero O, et al. 2005. Development and application of a multiplex PCR procedure for the detection of DNA methylation in colorectal cancer. Oncol Rep 13: 325-328.
• Anzola M, Cuevas N, Lopez-Martinez M, Martinez de Pancorbo M, Burgos JJ, 2004. Patterns of methylation profiles as diagnostic markers for multiple hepatocellular carcinomas. Scand J Gastroenetrol 39: 246-251.
• Arnold CN, Goel A, Boland CR, 2003. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106: 66-73.
• Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, et al. 2004. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 10: 5998-6005.
• Baker EK, El-Osta A, 2003. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 290: 177-194.
• Ballestar E, Esteller M, 2002. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23: 1103-1109.
• Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al.-Saleem T, et al. 2003. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 63: 8695-8699.
• Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG, 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687-692.
• Blan JL, Wager M, Guilhot J, Kusy S, Bataille В, Chantereau T, et al. 2004. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68: 275-283.
• Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, et al. 2001. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20: 3528-3532.
• Chan EC, Lam SY, Tsang KW, Lam B, Ho JC, Fu KH, et al. 2002. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. Clin Cancer Res 8: 3741-3746.
• Chang HW, Chow V, Lam KY, Wei WI, Yuen A, 2002. Loss of E-Cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 94: 386-392.
• Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, et al. 2002. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8: 3669-3675.
• Chen W-D, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. 2005. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97: 1124-1132.
• Chim CS, Liang R, Tam CY, Kwong YL, 2001. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 19: 2033-2040.
• Cho В, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, et al. 2003. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys Res Commun 307: 52-63.
• Cottrell SE, 2004. Molecular diagnostic applications of DNA methylation technology. Clin Biochem 37: 595-604.
• Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P, 2004a. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10: 1887-1893.
• Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P, 2004b. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10: 6189-6193.
• Ehrlich M, 2002. DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
• Esteller M, 2005. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 205: 172-180.
• Esteller M, Corn PG, Baylin SB, Herman JG, 2001. A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
• Esteller M, Herman JG, 2004. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23: 1-8.
• Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, et al. 2005. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 97: 273-282.
• Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, et al, 2004. Methylated DNA collected by tampons - a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 13: 882-888.
• Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. 2005. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65: 1141-1145.
• Field JK, Liloglou T, Warrak S, Burger M, Becker E, Berlin K, et al. 2005. Methylation discriminators in NSCLC identified by a microarray based approach. Int J Oncol 27: 105-111.
• Fujiwara K, Fijimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, et al. 2005. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11: 1219-1225.
• Fulda S, Kuefer MU, Meyer E, van Valen F, Dockhorn-Dworniczak В, Debatin K-M, 2001. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865-5877.
• Gifford G, Paul J, Vasey PA, Kaye SB, Brown R, 2004. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10: 4420-4426.
• Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, De Juan C, Sanchez-Pernaute A, Torres A, et al. 2004. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol 24: 349-355.
• Gonzalgo ML, Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, et al. 2004. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 10: 7276-7283.
• Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, et al. 2004. Prognostic analysis of E-Cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10: 2784-2789.
• Grunau C, Sanchez C, Ehrlich M, van der Bruggen P, Hindermann W, Rodriguez C, et al. 2005. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 43: 11-24.
• Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. 2004. Clinical trial substantiates the predictive value of O-6-methylaguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874.
• Henrique R, Jeronimo C, 2004. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 46: 660-669.
• Hoque MO, Begom S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al. 2004. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64: 5511-5517.
• House MG, Guo M, Efron DT, Lillemoe KD, Cameron JL, Syphard JE, et al. 2003. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behaviour. J Gastrointest Surg 7: 1001-1014.
• Itano O, Ueda M, Kikuchi K, Hashimoto O, Hayatsu S, Kawaguchi M, et al. 2002. Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences. Oncogene 21: 789-797.
• Jaenisch R, Bird A, 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33(Suppl.): 245-254.
• Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. 2001. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659-1665.
• Jenuwein T, Allis CD, 2001. Translating the histone code. Science 293: 1074-1079.
• Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, et al. 2004. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 10: 4010-4014.
• Jones PA, Takai D, 2001. The role of DNA methylation in mammalian epigenetics. Science 293: 1068-1070.
• Kawakami T, Okamoto K, Ogawa O, Okada Y, 2004. XIST unmethylated DNA fragments in male-derived plasma as a tumor marker for testicular cancer. Lancet 363: 40-42.
• Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, et al. 2004. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. 22: 2363-2370.
• Kim WJ, Vo QN, Shrivastav M, Lataxes ТА, Brown KD, 2002. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 21: 3864-3871.
• Kimura N, Nagasaka T, Murakami J, Sasamoto H, Murakami M, Tanaka N, et al. 2005. Methylation profiles of genes utilizing newly developed CpG island methylation microarray on colorectal cancer patients. Nucleic Acids Res 33: e46.
• Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzyński DL, et al. 2004. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 3: 16.
• Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, et al. 2004. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10: 28-32.
• Laird PW, 2003. The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266.
• Laird PW, 2005. Cancer epigenetics. Hum Mol Genet 14: R65-R76.
• Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, et al. 2005. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 92: 2190-2194.
• Levenson VV, 2004. DNA methylation biomarkers of cancer: moving toward clinical application. Pharmacogenomics 5: 699-707.
• Lofton-Day C, Lesche R, 2003. DNA methylation markers in patients with gastrointestinal cancers. Current understanding, potential applications for disease management and development of diagnostic tools. Dig Dis 21: 299-308.
• Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C, 2005. Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics 5: 223-232.
• Marchevsky AM, Tsou JA, Laird-Offringa IA, 2004. Classification of individual lung cancer cell lines based on DNA methylation markers. Use of linear discriminant analysis and artificial neural networks. J Mol Diagn 6: 28-36.
• Martens JWM, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, et al. 2005. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65: 4101-4107.
• Miyamoto K, Ushijima T, 2005. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 35: 293-301.
• Mueller HM, Widschwendter M, 2003. Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn 3: 443-458.
• Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, et al. 2003. Molecular detection of p 16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 105: 491-493.
• Olopade OI, Wei M, 2003. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3: 417-420.
• Pakneshan P, Tetu В, Rabbani SA, 2004. Demethylation of urokinase promoter as a progostic marker in patients with breast carcinoma. Clin Cancer Res 10: 3035-3041.
• Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. 2000. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958.
• Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC, 2005. P-Cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11: 5869-5877.
• Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R, 2000. Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039-6044.
• Roman J, Castillejo JA, Jimenez A, Bornstein R, Gonzalez MG, del Carmen Rodriguez M, et al. 2001. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br J Haematol 113: 329-338.
• Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, del Carmen Rodriguez M, et al. 2002. 5’CpG island hypermethylation is associated with transcriptional silencing of the p21 CIP1/WAF1/SDI1 gene ancj confers poor prognosis in acute lymphoblastic leukemia. Blood 99: 2291-2296.
• Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, et al. 2005. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11: 8321-8325.
• Russo AL, Thiagalingam A, Pan H, Califano J, Cheng K-H, Ponte JF, et al. 2005. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 11: 2466-2470.
• Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, et al. 2004. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 64: 1425-1430.
• Sathyanarayana UG, Padar A, Suzuki M, Maruyama R, Shigematsu B, Hsieh J-T, et al. 2003. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancer and its relationship to clinicopathological features. Clin Cancer Res 9: 6395-6400.
• Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, et al. 2003. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606-8613.
• Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. 2005. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266.
• Siu LL, Chan JK, Wong KF, Choy C, Kwong YL, 2003. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 122: 70-77.
• Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D, 2004. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10: 5518-5522.
• Topaloglu O, Hoque MO, Tokumaru Y, Lee J, Ratovitski E, Sidransky D, et al. 2004. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10: 2284-2288.
• Tsou JA, Shen LY, Siegmund KD, Long TI, Laird PW, Seneviratne CK, et al. 2005. Distinct DNA methylation profdes in malignant mesothelioma, lung adenocarcinoma and non-tumor lung. Lung Cancer 47: 193-204.
• Ushijima T, 2005. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231.
• Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan Y-H, et al. 2004. Value of pl6INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10: 6119-6125.
• Widschendter A, Ivarssin L, Blassnig A, Mueller HM, Fiegl H, Wiedemair A, et al. 2004. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 109: 163-166.
• Widschwendter M, Siegmund KD, Mueller HM, Fiegl H, Marth C, Mueller-Holzner E, et al. 2004. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64: 3807-3813.
• Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P, 2001. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem 276: 39990-40000.